Skip to main content
. 2023 May 15;24:32. doi: 10.1186/s40360-023-00663-0

Fig. 3.

Fig. 3

OS trend in (a) patients with (n =30) or without (n =68) treatment-related cutaneous toxicity (p =0.0008); (b) patients with (n =27) or without (n =71) treatment-related gastrointestinal toxicity (p =0.5); (c) patients with (n =20) or without (n =78) treatment-related endocrinological toxicity (p =0.0005); and (d) patients with toxicity (n =75) or without toxicity (n =23) (p =0.006)